Thursday October 2
09.00-18.00 Registration is open between 09.00-18.00
11.00-12.00 Satellite Symposium I – Gilead
Global access challenges for HIV & HCV drugs
(moderator: Anna Mia Ekström, Sweden)
Global burden of HIV & HCV and treatment trends (Hans Rosling, Sweden)
An Overview of Gilead’s Access Program (Clifford Samuel, USA)
12.00-13.00 Lunch
Opening session (Magnus Gisslén, Sweden and Johanna Brännström, Sweden)
13.00-13.15 Welcome (Magnus Gisslén, Sweden)
13.15-14.00 Opening Plenary 1 – Achieved results from the Danish HIV cohort (Niels Obel, Denmark)
14.00-14.15 Discussion
14.15-14.45 Coffee and exhibition/posters
Plenary session I – Vaccine and immunotherapy. (Anders Sönnerborg, Sweden and Magnús Gottfreðsson, Iceland)
14.45-15.15 Plenary 2. Current status of HIV vaccine and immunotherapy research (Robin A Weiss, UK)
15.15-15.30 Discussion
Plenary session II –Last year’s most important achievements in the HIV research field (Anders Sönnerborg, Sweden and Magnús Gottfreðsson, Iceland)
15.30-16.00 Plenary 3. Top 5 in clinical HIV research 2013/14 (Margaret Johnson, UK)
16.00-16.15 Discussion
16.15-16.45 Plenary 4. Top 5 in basic HIV research 2013/14 (Francesca Chiodi, Sweden)
16.45-17.00 Discussion
17.15-18.15 Satellite Symposium II – GSK/ViiV
Tailoring Therapy Today: Talking about Dolutegravir
Welcome and Introduction (Magnus Gisslén, Sweden)
Living with HIV – a patients perspective and unmet needs (Ophelia Haanyama, Sweden)
Dolutegravir – a new treatment option in HIV - clinical background (Anders Sönnerborg, Sweden)
HIV treatment and drug interactions – considerations for using Dolutegravir in clinical practice (David Back, UK)
Q&A-session and Summary (Magnus Gisslén, Sweden)
Dinner
| Friday | October 3 |
|---|---|
| 07.30-18.00 | Registration is open between 07.30-18.00 |
| 08.00-09.00 Breakfast will be served | Satellite Symposium III – Janssen Welcome and Intruduction to MDR-Tb (Judith Bruchfeld, Sweden) Development of bedaquiline: A Rocky Road (Koen Andries, Belgium) Presentation of HIV speaker (Stefan Lindbäck, Sweden) HIV treatment; current status and future perspectives (Hans-Jürgen Stellbrink, Germany) Closing remarks (Judith Bruchfeld, Sweden) |
| Abstract Session I (Anders Blaxhult, Sweden and Matti Ristola, Finland) | |
| 09.00-09.20 | Oral 1 - The Occurrence of Transient Viral Blips during Suppressive Antiretroviral Treatment is Associated with High Baseline HIV-1 RNA Levels (Erik Sörstedt, Sweden) |
| 09.20-09.40 | Oral 2 - High incidence of high grade cervical neoplasia among women with HIV in Sweden (Christina Carlander, Sweden) |
| 09.40-10.00 | Oral 3 - Mild neurocognitive impairment is associated with CNS immunoactivation and neuronal injury in HIV-infected patients on effective antiviral therapy (Arvid Edén, Sweden) |
| 10.00-11.00 | Coffee and Poster exhibition |
| Plenary Session III – Cure and immune activation (Magnús Gottfreðsson, Iceland and Leo Flamholc, Sweden) | |
| 11.00-11.30 | Plenary 5. Current status of HIV cure research (David Margolis, USA) |
| 11.30-11.40 | Discussion |
| 11.40-12.10 | Plenary 6. The impact of persistent chronic immune activation in treated HIV (Peter Hunt, USA) |
| 12.10-12.20 | Discussion |
| 12.20-13.30 | Lunch |
| Plenary Session IV – Antiviral treatment (Matti Ristola, Finland and Magnus Gisslén, Sweden) | |
| 13.30-14.00 | Plenary 7. ART: How to balance the role of adverse events, efficacy, convenience, economy and risk of resistance (Graeme Moyle, UK) |
| 14.00-14.15 | Discussion |
| 14.15-14.45 | Plenary 8. New era of hepatitis C treatment in HIV/HCV co-infection (Stefan Zeuzem, Germany) |
| 14.45-15.00 | Discussion |
| 15.00-15.30 | Plenary 9. Alternative ART regimens for patients ineligible for nucs (José Gatell, Spain) |
| 15.30-15.45 | Discussion |
| 15.45-16.15 | Coffee and Poster exhibition |
| Plenary Session V (Anders Sönnerborg, Sweden and Aylin Yilmaz, Sweden) | |
| 16.15-16.45 | Plenary 10. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective (Christophe Fraser, UK) |
| 16.45-17.00 | Discussion |
| 17.00-17.30 | Plenary 11. Phylogeographic analysis of the global HIV epidemic (Dimitros Paraskevis, Greece) |
| 17.30-17.45 | Discussion |
| 17.45-18.00 | HIV Nordic 2014 Abstract Award (Lars Moberg, Sweden) |
| 18.00-18.15 | Concluding remarks (Anders Sönnerborg, Sweden) |